Related Experiment Video
Updated: Mar 19, 2026
Pharmacologic Induction of Epidermal Melanin and Protection Against Sunburn in a Humanized Mouse Model
Published on: September 7, 2013
Congenital melanocytic nevi: update in genetics and management
1aDivision of Dermatology, Phoenix Children's Hospital bUniversity of Arizona College of Medicine, Department of Child Health, Phoenix, AZ, USA.
Purpose Of Review:
The article intends to review recent updates in the management of congenital melanocytic nevi (CMN) and the evolving genomic landscape that has begun to shed light on the nature of nevogenesis, malignant potential, and possible therapeutic targets for those with melanoma and neurologic involvement.
Recent Findings:
CMN are the result of postzygotic somatic mutations involving key proteins in the mitogen-activated protein kinase pathway, primarily NRAS and BRAF. Complications include a spectrum of neurologic findings and development of melanoma. Patients with extracutaneous involvement may be better termed as having 'CMN syndrome'. MRI findings in high risk patients with multiple CMN may best predict clinical outcome.
Summary:
The management of patients with CMN is complex. Neurologic involvement and melanoma remain the two most devastating complications. New, genetically targeted therapies for patients with complications may be of value, and research for potential therapies is ongoing.
Insights
Recent advances in congenital melanocytic nevi (CMN) management focus on genetic insights into nevogenesis. Understanding these genetic underpinnings may reveal new therapeutic targets for melanoma and neurologic complications.
Area of Science:
- Dermatology
- Genetics
- Pediatrics
Background:
- Congenital melanocytic nevi (CMN) are common birthmarks with potential for serious complications.
- These nevi arise from postzygotic somatic mutations in the mitogen-activated protein kinase pathway, notably NRAS and BRAF.
- Extracutaneous involvement defines 'CMN syndrome,' necessitating comprehensive evaluation.
Purpose of the Study:
- To review current management strategies for CMN.
- To explore the genomic landscape influencing nevogenesis and malignant potential.
- To identify potential therapeutic targets for CMN-associated complications.
Main Methods:
- Literature review of recent updates in CMN management.
- Analysis of evolving genomic data related to nevogenesis.
- Synthesis of findings on melanoma and neurologic involvement in CMN.
Main Results:
- CMN pathogenesis involves somatic mutations in NRAS and BRAF.
- Melanoma and neurologic complications are the most severe outcomes.
- MRI findings can predict clinical outcomes in high-risk CMN patients.
Conclusions:
- CMN management is complex, with neurologic and oncologic risks being paramount.
- Genetically targeted therapies show promise for managing CMN complications.
- Ongoing research is crucial for developing novel treatment strategies.
Related Concept Videos
01:30Skin Cancer
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
01:19Pigmentation
Melanin occurs in two primary forms: eumelanin that provides black and brown pigment and pheomelanin that provides red color. Dark-skinned individuals produce more melanin than those with pale...
01:14Changes in Skin Color: Clinical Perspectives
Albinism
Albinism is a genetic disorder that affects (completely or partially) the coloring of skin, hair, and eyes. The defect is primarily...
01:20The Retinoblastoma Gene
01:20The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...